Dabigatran Etexilate 150 mg Hard Capsules – patient leaflet, side effects, dosage

1. What Dabigatran Etexilate 150 mg Hard Capsules are and what it is used for

Dabigatran Etexilate 150 mg Hard Capsules contains the active substance dabigatran etexilate and belongs to a group of medicines called anticoagulants. It works by blocking a substance in the body which is involved in blood clot formation.

Driving and using machines

Dabigatran Etexilate 150 mg Hard Capsules has no known effects on the ability to drive or use machines.

1. 3. How to take Dabigatran Etexilate 150 mg Hard Capsules

Dabigatran Etexilate 150 mg Hard Capsules is used in adults to:

• prevent blood clots in the brain (stroke) and other blood vessels in the body if you have a form of irregular heart rhythm called nonvalvular atrial fibrillation and at least one additional risk factor.
• treat blood clots in the veins of your legs and lungs and to prevent blood clots from re-occurring in the vein of your legs and lungs.

Dabigatran Etexilate 150 mg Hard Capsules is used in children to:

• treat blood clots and to prevent blood clots from reoccurring.

2. What you need to know before you take Dabigatran Etexilate 150 mg Hard Capsules

Do not take Dabigatran Etexilate 150 mg Hard Capsules

• if you are allergic to dabigatran etexilate or any of the other ingredients of this medicine (listed in section 6).
• if you have severely reduced kidney function.
• if you are currently bleeding.
• if you have a disease in an organ of the body that increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes).
• if you have an increased tendency to bleed. This may be inborn, of unknown cause or due to other medicines.
• if you are taking medicines to prevent blood clotting (e.g. warfarin, rivaroxaban, apixaban or heparin), except when changing anticoagulant treatment, while having a venous or arterial line and you get heparin through this line to keep it open or while your heart beat is being restored to normal by a procedure called catheter ablation for atrial fibrillation.
• if you have a severely reduced liver function or liver disease which could possibly cause death.
• if you are taking oral ketoconazole or itraconazole, medicines to treat fungal infections.
• if you are taking oral cyclosporine, a medicine to prevent organ rejection after transplantation.
• if you are taking dronedarone, a medicine used to treat abnormal heart beat.
• if you are taking a combination product of glecaprevir and pibrentasvir, an antiviral medicine used to treat hepatitis C
• if you have received an artificial heart valve which requires permanent blood thinning.

Warnings and precautions

Talk to your doctor before taking Dabigatran Etexilate 150 mg Hard Capsules. You may also need to talk to your doctor during treatment with this medicine if you experience symptoms or if you have to undergo surgery.

Tell your doctor if you have or have had any medical conditions or illnesses, in particular any of those included in the following list:

• if you have an increased bleeding risk, such as:

  • if you have been recently bleeding.
  • if you have had a surgical tissue removal (biopsy) in the past month.

  • if you have had a serious injury (e.g. a bone fracture, head injury or any injury

    requiring surgical treatment).

  • if you are suffering from an inflammation of the gullet or stomach.
  • if you have problems with reflux of gastric juice into the gullet.

  • if you are receiving medicines which could increase the risk of bleeding. See 'Other

    medicines and Dabigatran Etexilate 150 mg Hard Capsules' below.

  • if you are taking anti-inflammatory medicines such as diclofenac, ibuprofen, piroxicam.
  • if you are suffering from an infection of the heart (bacterial endocarditis).

  • if you know you have decreased kidney function, or you are suffering from

    dehydration (symptoms include feeling thirsty and passing reduced amounts of dark-coloured (concentrated) / foaming urine).

  • if you are older than 75 years.
  • if you are an adult patient and weigh 50 kg or less.
  • only if used for children: if the child has an infection around or within the brain.
• if you have had a heart attack or if you have been diagnosed with conditions that increase the risk to develop a heart attack.
• if you have a liver disease that is associated with changes in the blood tests. The use of this medicine is not recommended in this case.

Take special care with Dabigatran Etexilate 150 mg Hard Capsules

• if you need to have an operation:

  In this case Dabigatran Etexilate 150 mg Hard Capsules will need to be stopped temporarily due to an increased bleeding risk during and shortly after an operation. It is very important to take Dabigatran Etexilate 150 mg Hard Capsules before and after the operation exactly at the times you have been told by your doctor.

• if an operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):

  • it is very important to take Dabigatran Etexilate 150 mg Hard Capsules before and

    after the operation exactly at the times you have been told by your doctor.

  • tell your doctor immediately if you get numbness or weakness of your legs or problems

    with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.

• if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed.

Other medicines and Dabigatran Etexilate 150 mg Hard Capsules

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular you should tell your doctor before taking Dabigatran Etexilate 150 mg Hard Capsules, if you are taking one of the medicines listed below:

• Medicines to reduce blood clotting (e.g. warfarin, phenprocoumon, acenocoumarol, heparin, clopidogrel, prasugrel, ticagrelor, rivaroxaban, acetylsalicylic acid)
• Medicines to treat fungal infections (e.g. ketoconazole, itraconazole), unless they are only applied to the skin
• Medicines to treat abnormal heart beats (e.g. amiodarone, dronedarone, quinidine, verapamil). If you are taking verapamil containing medicines, your doctor may tell you to use a reduced dose of Dabigatran Etexilate 150 mg Hard Capsules depending on the condition for which it is prescribed to you. See section 3
• Medicines to prevent organ rejection after transplantation (e.g. tacrolimus, cyclosporine)

• A combination product of glecaprevir and pibrentasvir (an antiviral medicine used to treat hepatitis C)

  Dabigatran Etexilate 150 mg Hard Capsules can be used in adults and children aged 8 years or older who are able to swallow the capsules whole. Dabigatran Etexilate 150 mg Hard Capsules coated granules are available for the treatment of children below 12 years as soon as they are able to swallow soft food.

  Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

  Take Dabigatran Etexilate 150 mg Hard Capsules as recommended for the following conditions:

  Prevention of brain or body vessel obstruction by blood clot formation developing after abnormal heart beats and Treatment of blood clots in the veins of your legs and lungs including prevention of blood clots from re-occurring in the vein of your legs and lungs

  The recommended dose is 300 mg taken as one 150 mg capsule twice a day.

  If you are 80 years or older, the recommended dose is 220 mg taken as one 110 mg capsule twice daily.

  If you are taking verapamil containing medicines, you should be treated with a reduced Pradaxa dose of 220 mg taken as one 110 mg capsule twice a day, because your bleeding risk may be increased.

  If you have a potentially higher risk for bleeding, your doctor may decide to prescribe a dose of 220 mg taken as one 110 mg capsule twice a day.

  You can continue to take this medicine if your heart beat needs to be restored to normal by a procedure called cardioversion or by a procedure called catheter ablation for atrial fibrillation. Take Dabigatran Etexilate 150 mg Hard Capsules as your physician has told you.

  If a medical device (stent) has been deployed in a blood vessel to keep it open in a procedure called percutaneous coronary intervention with stenting, you can be treated with Dabigatran Etexilate 150 mg Hard Capsules after your physician has decided that normal control of blood coagulation is achieved. Take Dabigatran Etexilate 150 mg Hard Capsules as your physician has told you.

  Treatment of blood clots and prevention of blood clots from reoccurring in children

  Dabigatran Etexilate 150 mg Hard Capsules should be taken twice daily, one dose in the morning and one dose in the evening, at approximately the same time every day. The dosing interval should be as close to 12 hours as possible.

  The recommended dose depends on weight and age. Your doctor will determine the correct dose. Your doctor may adjust the dose as treatment progresses. Keep using all other medicines, unless your doctor tells you to stop using any.

  Table 1 shows single and total daily Dabigatran Etexilate 150 mg Hard Capsules doses in milligrams (mg). The doses depend on weight in kilograms (kg) and age in years of the patient.

  Table 1: Dosing table for Dabigatran Etexilate 150 mg Hard Capsules

Single doses requiring combinations of more than one capsule:

300 mg: two 150 mg capsules or four 75 mg capsules

260 mg: one 110 mg plus one 150 mg capsule or one 110 mg plus two 75 mg capsules 220 mg: as two 110 mg capsules

185 mg: as one 75 mg plus one 110 mg capsule

150 mg: one 150 mg capsule or two 75 mg capsules

How to take Dabigatran Etexilate 150 mg Hard Capsules

Dabigatran Etexilate 150 mg Hard Capsules can be taken with or without food. The capsule should be swallowed whole with a glass of water, to ensure delivery to the stomach. Do not break, chew, or empty the pellets from the capsule since this may increase the risk of bleeding.

Instructions for opening the blisters

The following pictogram illustrates how to take Dabigatran Etexilate 150 mg Hard Capsules out of the blister

1

Tear off one individual blister from the blister card along the

perforated line

Peel off the backing foil and remove the capsule.

2

• Do not push the capsules through the blister foil.

• Do not peel off the blister foil until a capsule is required.

  If you would like this leaflet in a different format please contact the licence holder at the above address. Change of anticoagulant treatment

  • Decreases in the number or even lack of white blood cells (which help to fight infections)

Without specific guidance from your doctor do not change your anticoagulant treatment.

• Yellowing of the skin or whites of the eyes, caused by liver or blood problems
• Hair loss

If you take more Dabigatran Etexilate 150 mg Hard Capsules than you should

Taking too much of this medicine increases the risk of bleeding. Contact your doctor immediately if you have taken too many capsules. Specific treatment options are available.

In the trial program the rate of heart attacks with Dabigatran Etexilate 150 mg Hard Capsules was higher than with warfarin. The overall occurrence was low. No imbalance in the rate of heart attacks was observed in patients treated with dabigatran versus patients treated with placebo.

If you forget to take Dabigatran Etexilate 150 mg Hard Capsules

A forgotten dose can still be taken up to 6 hours prior to the next due dose. A missed dose should be omitted if the remaining time is below 6 hours prior to the next due dose. Do not double a dose to make up for a forgotten dose.

Treatment of blood clots and prevention of blood clots from reoccurring in children

Common (may affect up to 1 in 10 people):

If you stop taking Dabigatran Etexilate 150 mg Hard Capsules

• A fall in the number of red cells in the blood

Take Dabigatran Etexilate 150 mg Hard Capsules exactly as prescribed. Do not stop taking this medicine without talking to your doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early. Contact your doctor if you experience indigestion after taking Dabigatran Etexilate 150 mg Hard Capsules.

• A fall in the number of platelets in the blood
• Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction
• Sudden change of the skin which affects its colour and appearance
• Haematoma formation
• Nosebleed

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

• Reflux of gastric juice into the gullet
• Vomiting

4. Possible side effects

• Feeling sick
• Frequent loose or liquid bowel movements

Like all medicines, this medicine can cause side effects, although not everybody gets them.

• Indigestion
• Hair loss

Dabigatran Etexilate 150 mg Hard Capsules affects blood clotting, so most side effects are related to signs such as bruising or bleeding. Major or severe bleeding may occur, these constitute the most serious side effects and, regardless of location, may become disabling, life-threatening or even lead to death. In some cases these bleedings may not be obvious.

• Liver enzymes increased

Uncommon (may affect up to 1 in 100 people):

• Decrease in the number of white blood cells (which help to fight infections)
• Bleeding may happen into the stomach or bowel, from the brain, from the rectum, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), or under the skin

If you experience any bleeding event that does not stop by itself or if you experience signs of excessive bleeding (exceptional weakness, tiredness, paleness, dizziness, headache or unexplained swelling) consult your doctor immediately. Your doctor may decide to keep you under closer observation or change your medicine.

• A fall in the amount of haemoglobin in the blood (the substance in the red blood cells)
• A decrease in the proportion of blood cells
• Itching

Tell your doctor immediately, if you experience a serious allergic reaction which causes difficulty in breathing or dizziness.

• Coughing of blood or blood stained sputum
• Belly ache or stomach ache
• Inflammation of the gullet and stomach

Possible side effects are listed below, grouped by how likely they are to happen.

• Allergic reaction
• Difficulty in swallowing

Prevention of brain or body vessel obstruction by blood clot formation developing after abnormal heart beats

• Yellowing of the skin or whites of the eyes, caused by liver or blood problems

Not known (frequency cannot be estimated from the available data):

Common (may affect up to 1 in 10 people):

• Lack of white blood cells (which help to fight infections)
• Bleeding may happen from the nose, into the stomach or bowel, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), or under the skin
• Serious allergic reaction which causes difficulty in breathing or dizziness
• Serious allergic reaction which causes swelling of the face or throat
• A fall in the number of red cells in the blood
• Difficulty in breathing or wheezing
• Belly ache or stomach ache
• Bleeding
• Indigestion
• Bleeding may happen into a joint or from an injury, from a surgical incision, or from the site of entry of an injection or from the site of entry of a catheter into a vein
• Frequent loose or liquid bowel movements
• Feeling sick
• Bleeding may happen from piles
• Ulcer in the stomach or bowel (incl. ulcer in the gullet)

Uncommon (may affect up to 1 in 100 people):

• Unusual laboratory test results on liver function
• Bleeding

• Bleeding may happen from piles, from the rectum, or in the brain

  Reporting of side effects

• Haematoma formation

  If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

• Coughing of blood or blood stained sputum
• A fall in the number of platelets in the blood
• A fall in the amount of haemoglobin in the blood (the substance in the red blood cells)

• Allergic reaction

  By reporting side effects, you can help provide more information on the safety of this medicine.

• Sudden change of the skin which affects its colour and appearance
• Itching

5. How to store Dabigatran Etexilate 150 mg Hard Capsules

• Ulcer in the stomach or bowel (incl. ulcer in the gullet)

• Inflammation of the gullet and stomach

  Keep this medicine out of the sight and reach of children.

• Reflux of gastric juice into the gullet

  Do not use this medicine after the expiry date which is stated on the carton, blister after “EXP”. The expiry date refers to the last day of that month.

• Vomiting

• Difficulty in swallowing

  Do not store above 30°C. Store in the original package in order to protect from moisture. If the tablets become discoloured or show any signs of deterioration, seek the advice of your pharmacist who will advise you what to do.

• Unusual laboratory test results on liver function

Rare (may affect up to 1 in 1000 people):

Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

• Bleeding may happen into a joint, from a surgical incision, from an injury, from the site of entry of an injection or from the site of entry of a catheter into a vein
• Serious allergic reaction which causes difficulty in breathing or dizziness

6. Contents of the pack and other information

• Serious allergic reaction which causes swelling of the face or throat

• Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction

  What Dabigatran Etexilate 150 mg Hard Capsules Contain

• A decrease in the proportion of blood cells

• Liver enzymes increased

  The active substance is dabigatran. Each hard capsule contains 172.95 mg dabigatran etexilate (as mesilate) equivalent to 150 mg of dabigatran etexilate.

• Yellowing of the skin or whites of the eyes, caused by liver or blood problems

  • The other ingredients are tartaric acid, acacia, hypromellose 2910, dimeticone 350, talc and hydroxypropyl cellulose.

Not known (frequency cannot be estimated from the available data):

• Difficulty in breathing or wheezing

• Decreases in the number or even lack of white blood cells (which help to fight infections)

  The capsule shell contains carrageenan, potassium chloride, titanium dioxide (E-171), and hypromellose 2910, FD & C blue 2/Indigo carmine (E-132).

• Hair loss

In a clinical trial the rate of heart attacks with Dabigatran Etexilate 150 mg Hard Capsules was numerically higher than with warfarin. The overall occurrence was low.

What Dabigatran Etexilate 150 mg Hard Capsules looks like and contents of the pack

Dabigatran Etexilate 150 mg Hard Capsules are hard capsules off white to pale yellow coloured pellets filled in blue cap and white to off white body hard capsules size 0 .

Treatment of blood clots in the veins of your legs and lungs including prevention of blood clots from re-occurring in the veins of your legs and/or lungs

This medicine is available in packs containing:

Common (may affect up to 1 in 10 people):

10 x 1, 30 x 1 or 60 x 1 hard capsules in perforated Aluminum /OPA-ALU-PVC unit dose blisters.

• Bleeding may happen from the nose, into the stomach or bowel, from the rectum, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), or under the skin

  Not all pack sizes may be marketed.

• Indigestion

  Marketing Authorisation Holder and Manufacturer:

Uncommon (may affect up to 1 in 100 people):

Relonchem Ltd.,

• Bleeding

  Cheshire House, Gorsey Lane,

• Bleeding may happen into a joint or from an injury

  Widnes, Cheshire, WA8 0RP, UK.

• Bleeding may happen from piles

• A fall in the number of red cells in the blood

  PL 20395/0479

• Haematoma formation

• Coughing of blood or blood stained sputum

  This leaflet was last revised in December 2025.

• Allergic reaction

• Sudden change of the skin which affects its colour and appearance

  POM

• Itching
• Ulcer in the stomach or bowel (incl. ulcer in the gullet)
• Inflammation of the gullet and stomach
• Reflux of gastric juice into the gullet
• Feeling sick
• Vomiting
• Belly ache or stomach ache
• Frequent loose or liquid bowel movements
• Unusual laboratory test results on liver function
• Liver enzymes increased

Rare (may affect up to 1 in 1000 people):

• Bleeding may happen, from a surgical incision, or from the site of entry of an injection or from the site of entry of a catheter into a vein or from the brain
• A fall in the number of platelets in the blood
• Serious allergic reaction which causes difficulty in breathing or dizziness
• Serious allergic reaction which causes swelling of the face or throat
• Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction
• Difficulty in swallowing

Not known (frequency cannot be estimated from the available data):

• Difficulty in breathing or wheezing
• A fall in the amount of haemoglobin in the blood (the substance in the red blood cells)
• A decrease in the proportion of blood cells

0.6

VERSION XXXXX DATE 23.12.2025

NO. OF COLORS 01

PRODUCT NAME

Dabigatran Etexilate Hard Capsules

██ Black

PRODUCT LICENCE NO.

20395-0479

Pil

COUNTRY

UK (English)

240 x 480 mm

MANUFACTURER

Healthnova

STRENGTH

PACK SIZE

150 mg

-

SOFTWARE

ARTIST

Adobe illustrator CC Gurukiran

FONT & SIZE

Arial Narrow (24 pt, 9 pt)

REMARKS

-

REASON FOR CHANGE

Comments amended as per communication with Steph on 23.12.2025 and dimension revised as per communication with Steph on 22.12.2025 (Awaiting for CMO Confirmation)